Liang, Kevin Y. H.
Farjoun, Yossi
Forgetta, Vincenzo
Chen, Yiheng
Yoshiji, Satoshi
Lu, Tianyuan
Richards, J. Brent http://orcid.org/0000-0002-3746-9086
Funding for this research was provided by:
Canadian Institutes of Health Research (365825, 409511, 100558, 169303)
McGill Interdisciplinary Initiative in Infection and Immunity
Lady Davis Institute for Medical Research
Fondation de l'Hôpital général juif
Canadian Foundation for Innovation
NIH Foundation
Cancer Research UK (C18281/A29019)
Génome Québec
Public Health Agency of Canada
McGill University
Fonds de Recherche du Québec - Santé
Article History
Received: 2 November 2022
Accepted: 22 March 2023
First Online: 2 April 2023
Declarations
:
: JBR’s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. JBR is the CEO of 5 Prime Sciences (ExternalRef removed), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. VF, YF, and TL are employees of 5 Prime Sciences. Authors KYHL, YC, SY declares that they have no conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: This article does not contain any studies with human participants.